EXEL
Exelixis Inc
NASDAQ: EXEL · HEALTHCARE · BIOTECHNOLOGY
$53.13
-0.69% today
Updated 2026-06-12
Market cap
$13.35B
P/E ratio
17.59
P/S ratio
5.62x
EPS (TTM)
$3.02
Dividend yield
—
52W range
$34 – $54
Volume
2.6M
Exelixis Inc (EXEL) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed EXEL price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$53.13
Today
Analyst consensus
$47.35
-10.88% · 12M
2030 Base
$58.80
+10.67% future
NPV today
$43.79
@ 7% WACC
23 analysts:
10 Buy11 Hold3 Sell
Management guidance
No specific multi-year revenue guidance disclosed in recent materials. CEO Michael Morrissey has emphasized strong execution of oncology pipeline, particularly cabozantinib (Cabometyx) and next-gen programs like zanzalintinib. Company guided 2026 revenue to ~$2.64B (13.6% growth) and 2027 to ~$2.97B (12.7% growth) based on analyst consensus, with focus on expanding colorectal cancer and other solid tumor indications through Phase 3 trials.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
EXEL · Exelixis Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$26.71
NPV today: $19.89
Base case (2030)
$58.80
NPV today: $43.79
Bull case (2030)
$106.93
NPV today: $79.64
WallStSmart.com
EXEL financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.8B | $3.2B | $3.6B | $4.0B | $4.2B |
| Revenue growth | 7.0% | 18.5% | 15.6% | 13.8% | 9.1% | 5.8% |
| Net margin | — | 31.3% | 32.5% | 33.0% | 33.1% | 33.3% |
| EPS | $3.03 | $3.40 | $4.05 | $4.65 | $5.05 | $5.35 |
| Diluted shares | — | 253M | 255M | 257M | 259M | 261M |
| Net debt | — | $-432.33M | $-932.26M | $-1.50B | $-2.12B | $-2.78B |
| P/S multiple | — | 3.0x | 3.0x | 3.0x | 3.0x | 3.0x |
| Implied price (base) | — | $34.27 | $41.00 | $48.06 | $53.95 | $58.80 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $4.2B | $4.2B | $4.2B |
| P/S multiple | 1.0x | 3.0x | 6.0x |
| Diluted shares | 261M | 261M | 261M |
| Net debt | $-2.78B | $-2.78B | $-2.78B |
| Implied P/E † | 5x | 11x | 20x |
| 2030 Price | $26.71 | $58.80 | $106.93 |
| NPV @ 7% | $19.89 | $43.79 | $79.64 |
† Implied P/E: Multiples remain elevated across all three scenarios because EXEL is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $58.80 base case
EXEL catalysts and risks
Growth catalysts
+ Phase 3 STELLAR-316 trial for zanzalintinib + Merck KEYTRUDA (colorectal cancer) initiating mid-2026; potential accelerated approval pathway given unmet need
+ FDA NDA acceptance for zanzalintinib combo (filed Feb 2026) — decision expected 2H 2026, represents new revenue stream beyond cabozantinib
+ Cabozantinib label expansions (RCC, HCC, medullary thyroid, colorectal) driving volume growth; international penetration improving (5Y revenue CAGR 18.6%)
+ Potential M&A or strategic partnerships in oncology pipeline (recent Merck collaboration suggests willingness to partner/co-develop higher-upside assets)
Key risks
- Heavy reliance on cabozantinib (legacy drug with patent cliff risk post-2027 in key jurisdictions; generic/biosimilar competition could compress margins)
- Zanzalintinib development risk — Phase 3 STELLAR-316 must demonstrate benefit over standard-of-care; colorectal market crowded with checkpoint inhibitors + TKI combos
- Analyst sentiment downgraded YTD (Strong Buy ratings fell from 8 to 5; Morgan Stanley, Wells Fargo downgraded); consensus price target $47.35 vs. current $49.90 suggests limited upside
- P/E 16.5x elevated for biotech; profit margin 35.1% is high but dependent on single-asset revenue concentration; any pipeline setback could trigger 15-20% selloff
Methodology · Exelixis Inc 2030 stock forecast model
Exelixis Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 23 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (4% cumulative for EXEL by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-2.78B by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.385) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 3.0x / bull 6.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
EXEL price target FAQ
What is the EXEL price target for 2030?
WallStSmart's Exelixis Inc 2030 base case is $58.80 per share, with a bull case of $106.93 and bear case of $26.71. The NPV of the base case discounted to today at 7% WACC is $43.79.
How is the Exelixis Inc 2030 stock forecast calculated?
The EXEL 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the EXEL price target account for dilution?
Exelixis Inc is projected to grow diluted share count from 251M to 261M by 2030 (a 4% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 4%.
What is the analyst consensus on EXEL stock?
23 analysts cover EXEL with an average 12-month price target of $47.35. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.